Recently, a B cell-targeted biological agent, belimumab, which explicitly inhibits the B cell activating factor (BAFF), has been shown to alleviate clinical symptoms and reduce the production of immunological abnormalities in SLE patients. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.